CompletedNot Applicable

The Aortic Valve DECalcification (AVADEC) Trial

Denmark389 participantsStarted 2018-01-12

Plain-language summary

Aortic stenosis is a common heart valve disease and due to the growing elderly population the prevalence is increasing. The disease is progressive with increasing calcification of the valve cusps. A few attempts with medical preventive treatment have failed, thus presently the only effective treatment of aortic stenosis is surgery. This study will examine the effect of menaquinone-7 (MK-7) supplementation on progression of aortic valve calcification (AVC). The investigators hypothesize that MK-7 supplementation will slow down the calcification process.

Who can participate

Age range65 Years – 75 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Participants in the Danish Cardiovascular Screening Trial (Trials. 2015 Dec 5;16:554) with an aortic valve calcification score above 300, but without aortic valve stenosis are eligible. Exclusion Criteria: * Known aortic valve disease (peak velocity ≥3.0 m/s) * History of venous thrombosis or other coagulation disorders or use of vitamin K antagonists * Disorders of calcium and phosphate metabolism * A life-expectancy \< 5 years

What they're measuring

Aortic valve calcification

Timeframe: From baseline to two years of follow-up

Trial details

NCT IDNCT03243890

SponsorAxel Diederichsen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-05-01

View on ClinicalTrials.gov More Aortic Valve Stenosis trials